Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors

Molecular Pharmacology

Volumn 61, Issue 4, 2002, Pages 720-728

  Lazo, John S ^a   Nemoto, Kaoru ^a   Pestell, Katharine E ^a   Cooley, Kathleen ^a   Southwick, Eileen C ^a   Mitchell, Douglas A ^b   Furey, William ^b   Gussio, Rick ^c   Zaharevitz, Daniel W ^c   Joo, Beomjun ^d   Wipf, Peter ^d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 NAPHTHOQUINONE DERIVATIVE; 2,3 BIS(2 HYDROXYETHYLSULFANYL)[1,4]NAPHTHOQUINONE; NSC 102381; NSC 102539; NSC 105326; NSC 107043; NSC 113467; NSC 115447; NSC 117271; NSC 125248; NSC 128981; NSC 129077; NSC 129141; NSC 130442; NSC 135879; NSC 135880; NSC 139049; NSC 26654; NSC 327705; NSC 4056; NSC 43334; NSC 5; NSC 50554; NSC 5069; NSC 607; NSC 668394; NSC 672121; NSC 74702; NSC 77284; NSC 91101; NSC 92217; NSC 93957; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; QUINONE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SELECTIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; INHIBITION KINETICS; MITOSIS; MOLECULAR MODEL; MOUSE; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

AMINO ACID MOTIFS; BINDING SITES; CDC25 PHOSPHATASE; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIVISION; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HUMANS; KINETICS; MODELS, MOLECULAR; NAPHTHOQUINONES; TUMOR CELLS, CULTURED;

EID: 18344375627     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.61.4.720     Document Type: Article

References (35)

1. Role of Cdc25A phosphatase in human breast cancer
2. RIBBONS 2.0
3. Dual-specific Cdc25B phosphatase: In search of the catalytic acid
4. Form and function in protein dephosphorylation
5. The cell cycle Cdc25A tyrosine phosphatase is activated in degenerating postmitotic neurons in Alzheimer's disease
6. Synthese von 14-dithinen aus derivaten des maleinimids
7. Crystal structure of the catalytic domain of the human cell cycle control phosphatase Cdc25A
8. 2/M progression
9. Cdc25 cell-cycle phosphatase as a target of c-myc
10. Cdc25 phosphatases as potential human oncogenes
11. A common pharmacophore for epothilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells
12. Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition
13. Differential expression of Cdc25 cell-cycle-activating phosphatases in human colorectal carcinoma
14. Cdc25A is a novel phosphatase functioning early in the cell cycle
15. HINT: A new method of empirical hydrophobic field calculation for CoMFA
16. Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25
17. Synthesis, CoMFA analysis, and receptor docking of 3,5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists
18. Rapid destruction of human Cdc25A in response to DNA damage
19. Derivation of class II force fields: V. Quantum force field for amides, peptides, and related compounds
20. p55Cdc25 is a nuclear protein required for the initiation of mitosis in human cells
21. Human Cdc25A inactivation is response to S phase inhibition and its role in preventing premature mitosis
22. An additional homolog of the fission yeast cdc25+ gene occurs in humans and is highly expressed in some cancer cells
23. Cell cycle regulation by the Cdc25 phosphatase family
24. Inhibition of hepatoma cell growth in vitro by arylating and non-arylating K vitamin analogs
25. Studies on antianaphylactic agents-III
26. Small molecule inhibitors of dual specificity protein phosphatases
27. 2/M phase transition of the cell cycle
28. A targeted library of small molecule, tyrosine and dual specificity phosphatase inhibitors derived from a rational core design and random side chain variation
29. Synthesis and cytotoxic activities of 6-chloro-7-arylamino-5,8-isoquinolinediones
30. 2
31. Crystal structure of the MAPK phosphatase Pyst1 catalytic domain and implications for regulated activation
32. Cdc25 inhibition and cell cycle arrest by a synthetic thioalkyl vitamin K analogue
33. Disruption of insulin-like growth factor-1 signaling and down-regulation of Cdc2 by SC-ααδ9, a novel small molecule antisignaling agent identified in a targeted array library
34. Alternative splicing in the regulatory region of the human phosphatases Cdc25A and Cdc25C
35. Serine/threonine protein phosphatases